COMP <GO>
CRMD vs UNH // REVENUE GROWTH (YOY)
CorMedix Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CRMD 7
— UNH 5
▲ REVENUE GROWTH (YOY) LEADER: CRMD
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
revenue-growth
180.00%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 88.57% | -0.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | 11.47% | +34.03 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 16.4x | -13.45 | CRMD | /valuation <GO> |
| Free Cash Flow Yield | — | 6.48% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | 4.82% | +43.38 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | 3.14% | +49.16 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 180.00% | 6.46% | +173.54 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 3.12 | -1.31 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.6 | 59.2 | -8.60 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 17.7x | -14.24 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $368.83B | -$368.24B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | UNH REV | CRMD GROSS % | UNH GROSS % | CRMD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $447.57B | 88.5% | 88.7% | $172.8M | $16.07B |
| FY 2024 | $43.5M | $400.28B | 92.7% | 88.3% | -$50.7M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$38.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
UNH // BETA 0.33